{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.4"},{"groupId":"OG001","value":"3.3"}]}],"title":"Hospitalization due to Drug-related Adverse Event"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.3"},{"groupId":"OG001","value":"4.4"}]}],"title":"Transfusions Packed Red Blood Cells"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4"},{"groupId":"OG001","value":"0.6"}]}],"title":"Transfusions Whole Blood"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4"},{"groupId":"OG001","value":"0.6"}]}],"title":"Transfusions Platelets"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0.6"}]}],"title":"Transfusions Fresh Frozen Plasma"}],"denoms":[{"counts":[{"groupId":"OG000","value":"359"},{"groupId":"OG001","value":"180"}],"units":"Participants"}],"groups":[{"description":"pemetrexed and cisplatin followed by maintenance pemetrexed plus best supportive care","id":"OG000","title":"Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed"},{"description":"pemetrexed + cisplatin followed by placebo plus best supportive care","id":"OG001","title":"Pemetrexed + Cisplatin Followed by Placebo"}],"paramType":"NUMBER","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"Baseline randomization through 30-day post-discontinuation visit (up to 19.3 months)","title":"Percentage of Participants With Hospitalizations Due to Adverse Events or Requiring Transfusion (Resource Utilization)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}